NDT Advance Access originally published online on June 13, 2009
Nephrology Dialysis Transplantation 2009 24(11):3334-3342; doi:10.1093/ndt/gfp280
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Safety and tolerability of sirolimus treatment in patients with autosomal dominant polycystic kidney disease
1 Division of Nephrology, University Hospital Zürich 2 Institute of Physiology and Zürich Center for Integrative Human Physiology 3 Institute of General Practice and for Health Services Research, University of Zürich 4 Institute of Clinical Chemistry, University Hospital Zurich 5 Laboratory Medicine, University Hospital Basel 6 Division of Diagnostic Radiology, University Hospital Zürich, Switzerland
Correspondence and offprint requests to: Rudolf P. Wüthrich; E-mail: rudolf.wuethrich{at}usz.ch
 |
Abstract |
|---|
Background. We initiated a randomized controlled clinical trial to assess the effect of sirolimus on disease progression in patients affected by autosomal dominant polycystic kidney disease (ADPKD). Here we report the preliminary safety results of the first 6 months of treatment.
Method. A total of 25 patients were randomized to sirolimus 2 mg/day and 25 patients to no treatment except standard care. Treatment adherence was monitored electronically. At baseline and at Month 6, laboratory parameters were analysed and the urinary protein profile in 24-h urine collections was determined.
Results. Both treatment groups were well balanced for age, sex and renal function. In 94.1 ± 11.4% of the study days, patients in the sirolimus group were exposed to the drug when assuming a therapeutic efficacy duration of 30 h. At Month 6, the mean sirolimus dose and trough level were 1.28 ± 0.71 mg/day and 3.8 ± 1.9 µg/l, respectively. Glomerular (albumin, transferrin, IgG) and tubular (retinol-binding protein, 
1-microglobulin) protein excretion remained unchanged. Glomerular filtration rate also did not change significantly. Haematological parameters were similar in both groups, except for a mild reduction of the mean corpuscular volume of erythrocytes in patients receiving sirolimus. Lipid levels were similar in both groups. Adverse events were transient and mild, and no grade 3 or 4 events occurred. The incidence of infections was similar in the sirolimus group (80%) and the standard group (88%). The most common gastrointestinal adverse events were mucositis (72% in the sirolimus group versus 16% in the standard group, P = 0.0001) and diarrhoea (36% in the sirolimus versus 20% in the standard group, P = 0.345).
Conclusion. Treatment of ADPKD patients with sirolimus with a dose of 1–2 mg/day is safe and does not cause proteinuria or impairment of GFR. Treatment adherence was excellent. (ClinicalTrials.gov number, NCT00346918 [ClinicalTrials.gov] .)
Keywords: autosomal dominant polycystic kidney disease (ADPKD); safety; sirolimus; treatment adherence; urinary protein profile
Received for publication: 27. 2.09
Accepted in revised form: 20. 5.09
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  C. Ponticelli and F. Locatelli Autosomal dominant polycystic kidney disease and mTOR inhibitors: the narrow road between hope and disappointment Nephrol. Dial. Transplant., August 26, 2010; (2010) gfq527v1. [Full Text] [PDF]
|
|
|
|
|
|
C. Renken, D.-C. Fischer, G. Kundt, N. Gretz, and D. Haffner Inhibition of mTOR with sirolimus does not attenuate progression of liver and kidney disease in PCK rats Nephrol. Dial. Transplant., July 7, 2010; (2010) gfq384v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. E. Torres, A. Boletta, A. Chapman, V. Gattone, Y. Pei, Q. Qian, D. P. Wallace, T. Weimbs, and R. P. Wuthrich Prospects for mTOR Inhibitor Use in Patients with Polycystic Kidney Disease and Hamartomatous Diseases Clin. J. Am. Soc. Nephrol., July 1, 2010; 5(7): 1312 - 1329. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Perico, L. Antiga, A. Caroli, P. Ruggenenti, G. Fasolini, M. Cafaro, P. Ondei, N. Rubis, O. Diadei, G. Gherardi, et al. Sirolimus Therapy to Halt the Progression of ADPKD J. Am. Soc. Nephrol., June 1, 2010; 21(6): 1031 - 1040. [Abstract] [Full Text] [PDF]
|
|